Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SLV 306

Known as: SLV-306, SLV306 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Since the discovery of endothelin (ET)‐1 in 1988, the main components of the signalling pathway have become established… Expand
2012
2012
AIMS Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of natriuretic peptides… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in… Expand
2004
2004
Diabetic nephropathy is a serious complication of diabetes associated with a poor prognosis which deteriorates to end-stage renal… Expand
Review
2003
Review
2003
  • R. Tabrizchi
  • Current opinion in investigational drugs
  • 2003
  • Corpus ID: 19316501
SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for… Expand
Review
1992
Review
1992
In humans, the endothelins (ETs) comprise a family of three 21-amino-acid peptides, ET-1, ET-2 and ET-3. ET-1 is synthesised from… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5